Abstract 37P
Background
The "Hallmarks of Cancer" framework is foundational for understanding common organizational principles underlying diverse cancer types. However, the absence of a consensus gene set for cancer hallmarks leads to varied biological interpretations across studies. In this work, we established a unified cancer hallmark gene set by merging data from existing mapping resources and devising a framework for gene set mining.
Methods
We searched the NCBI PubMed database for publications from which a list of cancer hallmark genes could be extracted or reconstructed. Then, we performed a cancer hallmarks enrichment analysis on a list of differentially expressed genes between normal and tumor tissues across eleven solid tumor types.
Results
Consolidating hallmark genes from seven projects, we identified 6,763 genes associated with ten cancer hallmarks. We discovered a hallmark enrichment “fingerprint” specific to each tumor type. Notably, kidney cancers displayed the most extensive hallmark enrichment, underscoring the complexity of the disease. Hallmarks linked to immune function, such as “Evading immune destruction” and “Tumor promoting inflammation” were prominently enriched in kidney and CNS cancers (p<0.0001). “Tissue invasion and metastasis” was the single most prominent hallmark in skin and pancreatic cancers (p<0.0001), known to metastasize early. "Reprogramming energy metabolism" emerged as the hallmark particularly enriched in breast, ovarian, and uterine cancers (p<0.0001), suggesting the feasibility of metabolic approaches to target these cancers. The hallmark “Genome instability” was significantly enriched in cancers frequently associated with lifestyle choices, including colon, oesophageal, and liver cancers (p<0.05), and in cervical cancers, known to be linked to HPV infection (p<0.0001). To facilitate the analysis of cancer hallmarks, we developed an online tool (www.cancerhallmarks.com) to identify cancer-associated hallmarks from novel gene sets.
Conclusions
We established a consensus list of cancer hallmark genes and delineated unique patterns of hallmark enrichment across diverse tumors. Our findings hold potential pharmacological implications and enhance the utility of the hallmark concept as an effective organizational tool.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) in Hungary. O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - DNAJC1 inhibit the ferroptosis of glioma cells through stabilizing GPX4 by competing with TRIM21
Presenter: Min Chao
Session: Poster session 07
Resources:
Abstract
22P - Pre-clinical development of CVGBM: A therapeutic mRNA-based multiepitope vaccine for glioblastoma
Presenter: Ronja Mülfarth
Session: Poster session 07
23P - Germline testing in a selected cohort of non-small cell lung cancer (NSCLC) patients: Final results from the INHERITY LC study
Presenter: Maria Zurera Berjaga
Session: Poster session 07
24P - Assessment of an AI algorithm to classify germline variants in the ATM cancer predisposition gene
Presenter: Nooshin Bayat
Session: Poster session 07
25P - NGS-based identification of novel hereditary breast/ovarian cancer genes in patients with clinical features of genetic predisposition
Presenter: Ekaterina Kuligina
Session: Poster session 07
26P - Multi-feature cell free DNA analysis and ensemble machine learning for early detection of cancer
Presenter: Seongmun Jeong
Session: Poster session 07
27P - Molecular insights on cutaneous melanoma hyperpigmentation and therapy resistance
Presenter: Elena Andreucci
Session: Poster session 07
28P - Targeting YAP1 as a biomarker of resistance and therapeutic strategy in melanoma immunotherapy
Presenter: Szonja Kovács
Session: Poster session 07
29P - Considering intra-patient response variability in clinical trials: Implications for treatment efficacy and survival
Presenter: Caryn Geady
Session: Poster session 07
Resources:
Abstract
30P - CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors
Presenter: Yang Zheng
Session: Poster session 07